PRRT2 and non-small cell lung carcinoma: The intranuclear enrichment of PKCδ in gefitinib-resistant NSCLC promotes cell survival due to the transcription of anti-apoptotic molecules.200 The combination of sotrastaurin, a PKC inhibitor, and gefitinib significantly restored tumor sensitivity to gefitinib.